According to disclosures from the Hong Kong Stock Exchange on September 29, Changchun High-Tech Industry (Group) Co.,Ltd. (referred to as Changchun High-Tech Industry (Group) Co.,Ltd.) has submitted its IPO application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities International serving as its sole sponsor. Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) is already listed on the Shenzhen Stock Exchange.
The prospectus reveals that Changchun High-Tech Industry (Group) Co.,Ltd. is a leading innovation-driven pharmaceutical group in China, with business operations covering therapeutic biologics, chemical pharmaceuticals, vaccines, and traditional Chinese medicines, encompassing all major drug registration categories in China. According to Frost & Sullivan data, the company is among the few domestic pharmaceutical enterprises that have achieved full industrial chain capabilities including R&D, production, and commercialization across the aforementioned drug categories.
Guided by a differentiated innovation strategy, Changchun High-Tech Industry (Group) Co.,Ltd. has developed a competitive and diversified product portfolio that not only delivers strong financial performance but also continuously establishes a solid foundation for sustainable growth. In 2024, the company's pharmaceutical product sales revenue reached RMB 12.7 billion, achieving a scale of over RMB 10 billion for four consecutive years. Since 2017, Changchun High-Tech Industry (Group) Co.,Ltd. has been included in the "China's Top 100 Pharmaceutical Companies" list for eight consecutive years.
Changchun High-Tech Industry (Group) Co.,Ltd. has established a strong and diversified product portfolio in endocrine and metabolic diseases, women's health, immune and respiratory diseases, oncology, vaccines, and traditional Chinese medicines. During the track record period and as of September 23, 2025, the company successfully launched 13 new drug products, including the herpes zoster vaccine approved in January 2023 (the first and only domestically developed herpes zoster vaccine as of September 23, 2025); Injectable Firsekibart (Jinbeixin®) (China's first Class 1 innovative biological drug approved for acute gouty arthritis in June 2025); Progesterone Injection (II) (Jinsaixin®) approved in June 2024 (China's first subcutaneous water-soluble progesterone injection included in the 2024 National Medical Insurance Drug Catalog); and the liquid nasal spray influenza vaccine approved in August 2025.
Changchun High-Tech Industry (Group) Co.,Ltd. is also actively expanding the indication coverage of approved products to target broader patient populations. For example, Jinsai Growth Hormone was approved for ISS and Turner syndrome in 2024, becoming the only LAGH product in China with approved indications beyond PGHD, with its three indications covering approximately 82.3% of China's pediatric short stature population.
As of September 23, 2025, Changchun High-Tech Industry (Group) Co.,Ltd. possesses over 40 drug candidates in clinical stages or with submitted Investigational New Drug (IND) applications, including 14 candidates in Phase III clinical trials or New Drug Application (NDA) stages and 15 Class 1 innovative drugs. Multiple drug candidates demonstrate potential as global first-in-class or best-in-class treatments.
In terms of financial performance, for the years 2022, 2023, 2024, and the six months ended June 30, 2025, the company achieved revenues of approximately RMB 12.627 billion, RMB 14.566 billion, RMB 13.466 billion, and RMB 6.603 billion, respectively. During the same periods, annual/period profits were approximately RMB 4.215 billion, RMB 4.776 billion, RMB 2.708 billion, and RMB 932 million, respectively.
Comments